Onconetix (ONCO) S-1/A 19 May 22 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	3 Months Ended
	Mar. 31, 2022
Document Information Line Items
Entity Registrant Name	Blue Water Vaccines Inc.
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No. 1
Entity Central Index Key	0001782107
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 18,609,249	$ 1,928,474	$ 4,308,821
Prepaid expenses	90,005	234,551	242,853
Deferred offering costs	238,804	757,646
Receivable from related parties	164,515	152,524	44,805
Total current assets	19,102,573	3,073,195	4,596,479
Prepaid expenses, long-term	129,454		184,934
Property and equipment, net	15,399	11,502	15,667
Deposit	87,638		15,000
Total assets	19,335,064	3,084,697	4,812,080
Current liabilities
Accounts payable	907,538	582,605	68,668
Accrued expenses	1,893,438	1,055,515
Total current liabilities	2,800,976	1,638,120	68,668
Deferred rent			9,642
Total liabilities		1,638,120	78,310
Commitments and Contingencies (see Note 7)
Stockholders’ equity
Preferred stock, $0.00001 par value, 10,000,000 shares authorized at March 31, 2022 and December 31, 2021
Series Seed: 0 and 1,150,000 shares designated at March 31, 2022 and December 31, 2021, respectively; 0 and 1,146,138 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively; $0 and $15.4 million aggregate liquidation preference at March 31, 2022 and December 31, 2021, respectively		11	11
Common stock, $0.00001 par value, 250,000,000 shares authorized at March 31, 2022 and December 31, 2021; 11,048,587 and 3,200,000 shares outstanding at March 31, 2022 and December 31, 2021, respectively	110	32	32
Additional paid-in-capital	24,561,309	7,403,204	7,273,063
Accumulated deficit	(8,027,331)	(5,956,670)	(2,539,336)
Total stockholders’ equity	16,534,088	1,446,577	4,733,770
Total liabilities and stockholders’ equity	$ 19,335,064	$ 3,084,697	$ 4,812,080

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	10,000,000	10,000,000	1,150,000
Preferred stock, designated	0	1,150,000	1,150,000
Preferred stock, shares issued	0	1,146,138	1,146,138
Preferred stock, shares outstand	0	1,146,138	1,146,138
Aggregate liquidation preference shares (in Dollars)	$ 0	$ 15.4	$ 7.8
Common stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001	$ 0.00001
Common stock, shares authorized	250,000,000	250,000,000	2,300,000
Common stock, shares outstanding	11,048,587	3,200,000	3,200,000

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Operating costs and expenses
General and administrative	$ 1,615,569	$ 237,544	$ 2,092,304	$ 1,097,161
Research and development	455,092	88,237	1,325,030	524,908
Total operating expenses	2,070,661	325,781	3,417,334	1,622,069
Loss from operations	(2,070,661)	(325,781)	(3,417,334)	(1,622,069)
Other income
Interest income				22,603
Total other income				22,603
Net loss	(2,070,661)	(325,781)	(3,417,334)	(1,599,466)
Cumulative preferred stock dividends	96,359	137,687	627,391	559,928
Net loss applicable to common stockholder	$ (2,167,020)	$ (463,468)	$ (4,044,725)	$ (2,159,394)
Net loss per share attributable to common stockholder, basic and diluted (in Dollars per share)	$ (0.34)	$ (0.14)	$ (1.26)	$ (0.67)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	6,339,435	3,200,000	3,200,000	3,200,000

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 11	$ 32	$ 6,938,226	$ (939,870)	$ 5,998,399
Balance (in Shares) at Dec. 31, 2019	1,146,138	3,200,000
Stock-based compensation			334,837		334,837
Net loss				(1,599,466)	(1,599,466)
Balance at Dec. 31, 2020	$ 11	$ 32	7,273,063	(2,539,336)	4,733,770
Balance (in Shares) at Dec. 31, 2020	1,146,138	3,200,000
Stock-based compensation			41,721		41,721
Net loss				(325,781)	(325,781)
Balance at Mar. 31, 2021	$ 11	$ 32	7,314,784	(2,865,117)	4,449,710
Balance (in Shares) at Mar. 31, 2021	1,146,138	3,200,000
Balance at Dec. 31, 2020	$ 11	$ 32	7,273,063	(2,539,336)	4,733,770
Balance (in Shares) at Dec. 31, 2020	1,146,138	3,200,000
Stock-based compensation			130,141		130,141
Net loss				(3,417,334)	(3,417,334)
Balance at Dec. 31, 2021	$ 11	$ 32	7,403,204	(5,956,670)	1,446,577
Balance (in Shares) at Dec. 31, 2021	1,146,138	3,200,000
Issuance of common stock in initial public offering, net of $2.9 million of offering costs		$ 22	17,138,818		17,138,840
Issuance of common stock in initial public offering, net of $2.9 million of offering costs (in Shares)		2,222,222
Conversion of convertible preferred stock to common stock upon initial public offering	$ (11)	$ 56	(45)
Conversion of convertible preferred stock to common stock upon initial public offering (in Shares)	(1,146,138)	5,626,365
Stock-based compensation			19,332		19,332
Net loss				(2,070,661)	(2,070,661)
Balance at Mar. 31, 2022		$ 110	$ 24,561,309	$ (8,027,331)	$ 16,534,088
Balance (in Shares) at Mar. 31, 2022		11,048,587

Statements of Stockholders' E_2

Statements of Stockholders' Equity (Parentheticals)	3 Months Ended
	Mar. 31, 2022USD ($)
Statement of Stockholders' Equity [Abstract]
Offering costs, net	$ 2.9

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (2,070,661)	$ (325,781)	$ (3,417,334)	$ (1,599,466)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,300	1,232	4,890	3,056
Stock-based compensation	19,332	41,721	130,141	334,837
Write off of receivable from related party			22,242
Loss on disposal of property and equipment			1,199
Changes in assets and liabilities:
Prepaid expenses	144,546	(57,309)	8,302	(242,845)
Receivable from related parties	(11,991)	(5,056)	(114,961)	(36,475)
Prepaid expenses, long-term	(129,454)	46,233	184,934	(184,934)
Deposit	(87,638)
Accrued expenses	896,659		809,279	(57,385)
Accounts payable	351,816	42,412	336,715	50,291
Deferred rent			(9,642)	2,783
Net cash used in operating activities	(886,091)	(256,548)	(2,044,235)	(1,730,138)
Cash flows from investing activities
Purchase of property and equipment	(5,197)		(1,924)	(11,792)
Net cash used in investing activities	(5,197)		(1,924)	(11,792)
Cash flows from financing activities
Payment of deferred offering costs	(5,000)		(334,188)
Proceeds from issuance of common stock in initial public offering, net of underwriting discount	18,400,000
Payments of initial public offering costs	(822,937)
Net cash provided by financing activities	17,572,063		(334,188)
Net increase (decrease) in cash	16,680,775	(256,548)	(2,380,347)	(1,741,930)
Cash, beginning of period	1,928,474	4,308,821	4,308,821	6,050,751
Cash, end of period	18,609,249	4,052,273	1,928,474	4,308,821
Noncash investing and financing activities:
Deferred offering costs included in accounts payable and accrued expenses	233,804		$ 423,458
Conversion of convertible preferred stock to common stock upon initial public offering	45
Initial public offering costs included in accounts payable	$ 104,035

Organization and Basis of Prese

Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Organization and Basis of Presentation [Abstract]
Organization and Basis of Presentation	Note 1 — Organization and Basis of Presentation Organization and Nature of Operations Blue Water Vaccines Inc. (the “Company”) was formed on October 26, 2018, to focus on the research and development of transformational vaccines to prevent infectious diseases worldwide. The Company’s lead vaccine candidates, BWV -101 -102 -in-class -term -purpose -clinical Initial Public Offering On February 23, 2022, the Company completed its initial public offering (“IPO”) in which the Company issued and sold 2,222,222 Stock Split On November 24, 2021, the Company’s board of directors approved a 4 -for-1 Basis of Presentation The Company’s unaudited condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Liquidity and Financial Conditi

Liquidity and Financial Condition	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Liquidity and Financial Condition [Abstract]
Liquidity and Financial Condition	Note 2 — Liquidity and Financial Condition The Company has had limited operating activities to date, substantially all of which have been devoted to seeking licenses and engaging in research and development activities. The Company’s product candidates currently under development will require significant additional research and development efforts prior to commercialization. The Company has financed its operations since inception primarily using proceeds received from seed investors, and proceeds received upon the completion of its IPO. The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of March 31, 2022, the Company had cash of approximately $18.6 million, working capital of approximately $16.3 million and an accumulated deficit of approximately $8.0 million. On April 19, 2022, the Company completed a private placement in which it received approximately $7.0 million in net proceeds, after deducting placement agent fees and other initial offering expenses, see Note 11. The Company believes the existing cash at March 31, 2022, together with the net proceeds received upon the close of the private placement, will be sufficient to continue operations, satisfy its obligations and fund the future expenditures that will be required to conduct the clinical and regulatory work to develop its product candidates for at least one year after the date that these financial statements are available to be issued. As such, the Company determined that it is not probable based on projected cash flows that substantial doubt about the Company’s ability to continue as a going concern exists for the one -year The Company will require significant additional capital to make the investments it needs to execute its longer -term -clinical -term -term	Note 2 — Liquidity and Financial Condition The Company has had limited operating activities to date, substantially all of which have been devoted to seeking licenses and engaging in research and development activities. The Company’s product candidates currently under development will require significant additional research and development efforts prior to commercialization. The Company has financed its operations since inception primarily using proceeds received from seed investors. The Company has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of December 31, 2021, the Company had cash of approximately $1.9 million, working capital of approximately $1.4 million and an accumulated deficit of approximately $6.0 million. On February 23, 2022, the Company completed its initial public offering (“IPO”) in which the Company received approximately $17.2 million in net proceeds, after deducting the underwriting discount, and estimated offering expenses, see Note 10. The Company believes the existing cash at December 31, 2021, together with the net proceeds received upon the close of its IPO, will be sufficient to continue operations, satisfy its obligations and fund the future expenditures that will be required to conduct the clinical and regulatory work to develop its product candidates into the second quarter of 2023. As such, the Company determined that it is not probable based on projected cash flows that substantial doubt about the Company’s ability to continue as a going concern exists for the one -year The Company will require significant additional capital to make the investments it needs to execute its longer -term -clinical -term -term

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 — Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s financial statements relate to the valuation of common stock, stock -based Unaudited Interim Financial Statements The accompanying condensed balance sheet as of March 31, 2022, and the condensed statements of operations, the condensed statements of changes in stockholders’ equity, and the condensed statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements, and in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2022 and its results of operations and cash flows for the three months ended March 31, 2022 and 2021. The financial data and the other financial information disclosed in the notes to these condensed financial statements related to the three -month -Q -K Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of March 31, 2022 and December 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Property and Equipment Property and equipment consists of computers and office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight -line three seven -lived Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three -tier • • • In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Financial instruments, including cash, prepaid expenses, deferred offering costs, receivables from related parties, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short -term -financial -recurring Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third -party -process -process Research and Development The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Accrual estimates are based on several factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs. See Notes 5 and 7. In accordance with FASB ASC Topic 730 -10-25-1 Research and Development, Stock-Based Compensation The Company expenses stock -based -employees -date -based -vesting -line The Company estimates the fair value of stock option grants using the Black -Scholes -based Expected Term -based -life Expected Volatility -specific -based Common Stock Fair Value -party Risk -Free Interest Rate -free Expected Dividend The Company recognizes forfeitures of equity awards as they occur. Fair Value of Common Stock In order to determine the fair value of shares of common stock of the Company when issuing stock options prior to the IPO, its board of directors considered with input from third party valuations, among other things, contemporaneous valuations of the Company’s common stock. Given the absence of a public trading market of the Company’s capital stock prior to its IPO, its board of directors has exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of the Company common and preferred stock, including: • • • • • • • In estimating the fair market value of common stock of the Company, its board of directors first determined the equity value of its business using accepted valuation methods. The Company engaged a third -party After the completion of the IPO, the fair value of each share of common stock is based on the closing price of the Company’s common stock as reported by the Nasdaq Capital Market. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation allowance. Comprehensive Income (Loss) The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying condensed financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non -owner Warrants The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480 -10 Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity -10 -40 Derivatives and Hedging — Contracts in Entity’s Own Equity -40 -10 -classified If the warrants do not meet liability classification under ASC 480 -10 -40 -40 -40 -classified -classified -classified Net Loss Per Share Basic loss per share is computed by dividing the net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the Company’s preferred stock, warrants and options. Diluted loss per share excludes the shares issuable upon the conversion of preferred stock, as well as common stock options and warrants, from the calculation of net loss per share if their effect would be anti -dilutive The two -class -class The following securities were excluded from the computation of diluted shares outstanding due to the losses incurred in the periods presented, as they would have had an anti -dilutive Three Months Ended 2022 2021 Options to purchase shares of common stock 780,640 780,640 Series Seed Preferred Stock — 4,584,552 Warrants to purchase shares of common stock 111,111 — Total 891,751 5,365,192 New Accounting Pronouncement s In April 2012, the Jump -Start -public -public In August 2020, the FASB issued ASU No. 2020 -06 Debt — Debt with Conversion and Other Options (Subtopic 470 -20 ) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815 -40 ): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity -06 In October 2020, the FASB issued ASU 2020 -10 -10 In May 2021, the FASB issued ASU 2021 -04 -50 -40 -Classified -classified -classified -04 The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.	Note 3 — Summary of Significant Accounting Policies Basis of Presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Stock Split On November 24, 2021, the Company’s board of directors approved a 4 -for-1 Immaterial Correction to Previously Issued Financial Statements During the preparation of the financial statements for the nine months ended September 30, 2021, the Company identified an error in the disclosures related to the Series Seed liquidation preference, see Note 6 for related disclosures and defined terms. In previously issued financial statements, the Liquidation Preference Amount was incorrectly calculated and disclosed in the balance sheet at one times the Original Issue Price per share, plus unpaid cumulative dividends. As discussed in Note 6, the Liquidation Preference Amount has been two times the Original Issue Price per share, plus unpaid cumulative dividends. The Company evaluated this disclosure error based on the guidance provided by the SEC’s Staff Accounting Bulletin Materiality Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s financial statements relate to the valuation of common stock, stock -based Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of December 31, 2021 and 2020, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Property and Equipment Property and equipment consists of computers and office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight -line three seven -lived Fair Value of Financial Instruments Financial instruments, including cash, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short -term Fair Value Measurements Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three -tier • • • In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Deferred Offering Costs Deferred offering costs consist of legal, accounting, and other costs incurred through the balance sheet date that are directly related to the Company’s initial public offering and that will be charged to stockholders’ equity upon the completion of the IPO. Research and Development The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Accrual estimates are based on several factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs. See Notes 5 and 7. In accordance with FASB ASC Topic 730 -10-25-1 Research and Development, Stock-Based Compensation The Company expensed stock -based -employees -date -based -vesting -line The Company estimates the fair value of stock option grants using the Black -Scholes -based Expected Term -based -life Expected Volatility Common Stock Fair Value -party Risk -Free Interest Rate -free Expected Dividend The Company recognizes forfeitures of equity awards as they occur. Fair Value of Common Stock In order to determine the fair value of shares of common stock of the Company when issuing stock options and computing their estimated stock -based • • • • • • • In estimating the fair market value of common stock of the Company, its board of directors first determined the equity value of its business using accepted valuation methods. The Company engaged a third -party Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation allowance. Comprehensive Income (Loss) The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non -owner Net Loss Per Share Basic loss per share is computed by dividing the net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the Company’s preferred stock and options. Diluted loss per share excludes the shares issuable upon the conversion of preferred stock, as well as common stock options, from the calculation of net loss per share if their effect would be anti -dilutive The two -class -class The following were excluded from the computation of diluted shares outstanding due to the losses since inception, as they would have had an anti -dilutive Years Ended 2021 2020 Options to purchase shares of common stock 780,640 780,640 Series Seed Preferred Stock 4,584,552 4,584,552 Total 5,365,192 5,365,192 New Accounting Pronouncement s In April 2012, the Jump -Start -public -public On February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016 -02 Leases (Topic 842) -term -of-use -02 In December 2019, the FASB issued ASU No. 2019 -12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes -12 -12 -12 In August 2020, the FASB issued ASU No. 2020 -06 Debt — Debt with Conversion and Other Options (Subtopic 470 -20 ) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815 -40 ): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for public business entities except for smaller reporting companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2020 -06 In May 2021, the FASB issued ASU 2021 -04 -50 -40 -Classified -classified -classified The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements. Reclassification Certain amounts in the accompanying financial statements have been reclassified to conform to the current period’s presentation. The amounts reclassified were those related to consulting fee prepayments to our Chief Executive Officer (see Note 8), which were previously included in prepaid expenses in the historical balance sheet as of December 31, 2020, and were reclassified to receivable from related parties in the accompanying financial statements. The reclassification did not have any effect on the prior period net loss or cash flows from operations.

Balance Sheet Details

Balance Sheet Details	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Details	Note 4 — Balance Sheet Details Prepaid Expenses Prepaid expenses consisted of the following as of March 31, 2022 and December 31, 2021: As of As of Prepaid research and development $ 69,205 $ 203,910 Prepaid insurance — 4,842 Prepaid other 20,800 25,799 Total $ 90,005 $ 234,551 Accrued Expenses Accrued expenses consisted of the following as of March 31, 2022 and December 31, 2021: As of As of Accrued license fees $ 227,500 $ 225,000 Accrued research and development 564,634 300,182 Accrued deferred offering costs 187,500 246,236 Accrued compensation 680,537 234,265 Accrued insurance expense 118,988 — Accrued board of directors’ compensation 33,750 — Accrued other 80,529 49,832 Total $ 1,893,438 $ 1,055,515	Note 4 — Balance Sheet Details Prepaid Expenses Prepaid expenses consisted of the following as of December 31, 2021 and 2020: As of As of Prepaid research and development $ 203,910 $ 233,532 Prepaid insurance 4,842 4,321 Prepaid other 25,799 5,000 Total $ 234,551 $ 242,853 Accrued Expenses Accrued expenses consisted of the following as of December 31, 2021 and 2020: As of As of Accrued license fees $ 225,000 $ — Accrued research and development 300,182 — Accrued deferred offering costs 246,236 — Accrued compensation 234,265 — Accrued other 49,832 — Total $ 1,055,515 $ —

Significant Agreements

Significant Agreements	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Significant Agreements [Abstract]
Significant Agreements	Note 5 — Significant Agreements Oxford University Innovation Limited In December 2018, the Company entered into an option agreement Oxford University Innovation (“OUI”), which was a precursor to a license agreement (the “OUI Agreement”), dated July 16, 2019. Under the terms of the OUI Agreement, the Company holds an exclusive, worldwide license to certain specified patent rights and biological materials relating to the use of epitopes of limited variability and virus -like -up than for a bona fide amalgamation or reconstruction or compounds with its creditors or has a receiver or administrator appointed. OUI may also terminate if the Company opposes or challenges the validity of any of the patents or applications in the Licensed Technology, as defined in the OUI Agreement; raises the claim that the know -how For the three months ended March 31, 2022 and 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See Note 7. St. Jude Children’s Hospital The Company entered into a license agreement (the “St. Jude Agreement”), dated January 27, 2020, with St. Jude Children’s Research Hospital (“St. Jude”). Under the terms of the St. Jude Agreement, the Company holds an exclusive, worldwide license to certain specified patent rights and biological materials relating to the use of live attenuated streptococcus pneumoniae and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for streptococcus pneumoniae. The St. Jude Agreement will expire upon the expiration of the last valid claim contained in the licensed patent rights, unless terminated earlier. The Company is obligated to use commercially reasonable efforts to develop and commercialize the licensed product(s). The milestones include the following events: (i) complete IND enabling study; (ii) initiate animal toxicology study; (iii) file IND; (iv) complete Phase I Clinical Trial; (v) commence Phase II Clinical Trial; (vi) commence Phase III Clinical Trial; and, (vii) regulatory approval, U.S. or foreign equivalent. If the Company fails to achieve the development milestones contained in the St. Jude Agreement, and if the Company and St. Jude fail to agree upon a mutually satisfactory revised timeline, St. Jude will have the right to terminate the St. Jude Agreement. Either party may terminate the St. Jude Agreement in the event the other party (a) files or has filed against it a petition under the Bankruptcy Act (among other things) or (b) fails to perform or otherwise breaches its obligations under the St. Jude Agreement, and has not cured such failure or breach within sixty (60) days. The Company may terminate for any reason on thirty (30) days written notice. On May 11, 2022, the Company entered into an amendment to the St. Jude Agreement, whereby the royalty terms, milestones payments and licensing fees were amended. See Note 11 for more information on this amendment. For the three months ended March 31, 2022, the Company recognized approximately $3,000 for intellectual property licenses, which is recorded as research and development expenses. For the three months ended March 31, 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See Note 7 for additional information on the milestone payments as well as royalty obligations required under the St. Jude Agreement. Cincinnati Children’s Hospital Medical Center The Company entered into a license agreement (the “CHMC Agreement”), dated June 1, 2021, with Children’s Hospital Medical Center, d/b/a Cincinnati Children’s Hospital Medical Center (“CHMC”). Under the terms of the CHMC Agreement, the Company holds an exclusive, worldwide license (other than the excluded field of immunization against, and prevention, control, or reduction in the severity of gastroenteritis caused by rotavirus and norovirus in China and Hong Kong) to certain specified patent and biological materials relating to the use of norovirus nanoparticles and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing CHMC patents and related technology directed to a virus -like make all necessary regulatory filings and obtain all necessary regulatory approvals, to achieve milestones relating to development and sales, and report to CHMC on progress. The Company will also be obligated to pay the agreed upon development milestone payments to CHMC, as well as royalty payments, see Note 7 for additional information. The Company may terminate the CHMC Agreement for convenience, at any time prior to first commercial sale of a product or process by providing one hundred and eighty (180) days’ written notice to CHMC. It may also terminate for a CHMC uncured material breach. CHMC may terminate the CHMC Agreement for an uncured Company material breach or insolvency or bankruptcy. Pursuant to the terms of the CHMC Agreement, if the Company fails to achieve the milestones, and cannot mutually agree with CHMC on an amendment to the milestones, then CHMC will have the option of converting any and all of such exclusive licenses to nonexclusive licenses, to continue developing indications that have already entered development at any stage or in which the Company has invested in developing. CHMC may also terminate the CHMC Agreement to the fullest extent permitted by law in the countries of the worldwide territory, in the event the Company or its affiliates challenge or induce others set up challenges to the validity or enforceability of any of the Licensed Patents, as defined in the CHMC Agreement, and the Company will be obligated reimburse CHMC for its costs, including reasonable attorneys’ fees. For the three months ended March 31, 2022 and 2021, the Company did not incur any licensing fee payments for intellectual property licenses. See Note 7. Ology Bioservices, Inc. (which was later acquired by National Resilience, Inc.) The Company entered into a Master Services Agreement (“Ology MSA”), dated July 19, 2019, with Ology, Inc. (“Ology”) to provide services from time to time, including but not limited to technology transfer, process development, analytical method optimization, cGMP manufacture, regulatory affairs, and stability studies of biologic products. Pursuant to the Ology MSA, the Company and Ology shall enter into a Project Addendum for each project to be governed by the terms and conditions of the Ology MSA. The Company has entered into two Project Addendums as of March 31, 2022 and December 31, 2021. The initial Project Addendum was executed on October 18, 2019 and the Company was required to pay Ology an aggregate of approximately $4 million. Due to unforeseen delays associated with COVID -19	Note 5 — Significant Agreements Oxford University Innovation Limited In December 2018, the Company entered into an option agreement Oxford University Innovation (“OUI”), which was a precursor to a license agreement (the “OUI Agreement”), dated July 16, 2019. Under the terms of the OUI Agreement, the Company holds an exclusive, worldwide license to certain specified patent rights and biological materials relating to the use of epitopes of limited variability and virus -like -up -how For the years ended December 31, 2021 and 2020, the Company did not incur any licensing fee payments for intellectual property licenses. See Note 7. St. Jude Children’s Hospital The Company entered into a license agreement (the “St. Jude Agreement”), dated January 27, 2020, with St. Jude Children’s Research Hospital (“St. Jude”). Under the terms of the St. Jude Agreement, the Company holds an exclusive, worldwide license to certain specified patent rights and biological materials relating to the use of live attenuated streptococcus pneumoniae and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing a vaccine product candidate for streptococcus pneumoniae. The St. Jude Agreement will expire upon the expiration of the last valid claim contained in the licensed patent rights, unless terminated earlier. The Company is obligated to use commercially reasonable efforts to develop and commercialize the licensed product(s). The milestones include the following events: (i) complete IND enabling study; (ii) initiate animal toxicology study; (iii) file IND; (iv) complete Phase I Clinical Trial; (v) commence Phase II Clinical Trial; (vi) commence Phase III Clinical Trial; and, (vii) regulatory approval, U.S. or foreign equivalent. If the Company fails to achieve the development milestones contained in the St. Jude Agreement, and if the Company and St. Jude fail to agree upon a mutually satisfactory revised timeline, St. Jude will have the right to terminate the St. Jude Agreement. Either party may terminate the St. Jude Agreement in the event the other party (a) files or has filed against it a petition under the Bankruptcy Act (among other things) or (b) fails to perform or otherwise breaches its obligations under the St. Jude Agreement, and has not cured such failure or breach within sixty (60) days. The Company may terminate for any reason on thirty (30) days written notice. For the years ended December 31, 2021 and 2020, the Company recognized $11,000 and $15,000, respectively, for intellectual property licenses, which is recorded as research and development expenses. See Note 7 for additional information on the milestone payments as well as royalty obligations required under the St. Jude Agreement. Cincinnati Children’s Hospital Medical Center The Company entered into a license agreement (the “CHMC Agreement”), dated June 1, 2021, with Children’s Hospital Medical Center, d/b/a Cincinnati Children’s Hospital Medical Center (“CHMC”). Under the terms of the CHMC Agreement, the Company holds an exclusive, worldwide license (other than the excluded field of immunization against, and prevention, control, or reduction in the severity of gastroenteritis caused by rotavirus and norovirus in China and Hong Kong) to certain specified patent and biological materials relating to the use of norovirus nanoparticles and practice processes that are covered by the licensed patent rights and biological materials for the purpose of developing and commercializing CHMC patents and related technology directed to a virus -like challenge or induce others set up challenges to the validity or enforceability of any of the Licensed Patents, as defined in the CHMC Agreement, and the Company will be obligated reimburse CHMC for its costs, including reasonable attorneys’ fees. For the year ended December 31, 2021, the Company accrued licensing fee payments for intellectual property licenses and patent reimbursements, which are recorded as research and development expenses, in aggregate of $402,104. See Notes 4 and 7. Ology Bioservices, Inc. (which was later acquired by National Resilience, Inc.) The Company entered into a Master Services Agreement (“Ology MSA”), dated July 19, 2019, with Ology, Inc. (“Ology”) to provide services from time to time, including but not limited to technology transfer, process development, analytical method optimization, cGMP manufacture, regulatory affairs, and stability studies of biologic products. Pursuant to the Ology MSA, the Company and Ology shall enter into a Project Addendum for each project to be governed by the terms and conditions of the Ology MSA. The Company has entered into two Project Addendums as of December 31, 2021. The initial Project Addendum was executed on October 18, 2019 and the Company was required to pay Ology an aggregate of approximately $4 million. Due to unforeseen delays associated with COVID -19

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	Note 6 — Stockholders’ Equity Authorized Capital and Stock Split On February 23, 2022, the Company filed with the Secretary of State of the State of Delaware an amended and restated certificate of incorporation (the “A&R COI”), which became effective immediately. The Company’s board of directors and stockholders approved the A&R COI to be effective upon the closing of the IPO. There was no change to the Company’s authorized shares of common stock and preferred stock of 250,000,000 Common Stock As of March 31, 2022 and December 31, 2021, there were 11,048,587 and 3,200,000 Holders of the Company’s common stock are entitled to one vote for each share held of record, and are entitled upon liquidation of the Company to share ratably in the net assets of the Company available for distribution after payment of all obligations of the Company and after provision has been made with respect to each class of stock, if any, having preference over the common stock, currently including the Company’s preferred stock. The shares of common stock are not redeemable and have no preemptive or similar rights. On February 17, 2022, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Boustead Securities, LLC, acting as representative of the underwriters (“Boustead”), in relation to the Company’s IPO, pursuant to which the Company agreed to sell to the underwriters an aggregate of 2,222,222 The Company evaluated the terms of the warrants issued at the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC 480 and ASC 815 -40 -classified Preferred Stock Prior to the close of the IPO, the Company had designated 1,150,000 Conversion Each share of the Series Seed was convertible, at the option of the holder, at any time and from time to time, and without the payment of additional consideration by the holder, at a conversion price of $1.52 per share, subject to certain adjustments for stock splits, stock dividends, recapitalizations, and similar corporate transactions, into fully paid and non -assessable -effective Dividends Holders of the Series Seed were entitled to receive cumulative dividends at a per share rate of 8% per annum, compounded annually, on the initial investment amount commencing on the date of issue. Dividends were payable only when, as, and if declared by the Board of Directors or upon a Liquidation Event, as described below. Dividends on Series Seed were in preference to any dividend on the Company’s common stock. Upon the close of the IPO, aggregate cumulative dividends of $1,586,162 or $1.38 per Series Seed share were automatically converted into shares of common stock. Liquidation Preference In the event of certain voluntary or involuntary acquisition or sale transactions or upon the liquidation, dissolution or winding up of the Company (each, a “Liquidation Event”), the holders of Series Seed were entitled to receive out of the proceeds or assets of the Company legally available for distribution to its stockholders (the “Proceeds”), prior and in preference to any distribution of the Proceeds of such Liquidation Event to the holders of shares of common stock by reason of their ownership thereof, an amount (“the Liquidation Preference Amount”) determined based on the provisions of the Company’s COI. The COI provided that the Liquidation Preference Amount be calculated upon the occurrence of a Liquidation Event, based on the Company’s achievement of a Pre -Clinical -Clinical -Clinical -Clinical As of December 31, 2021, and all other prior historical periods, the Liquidation Preference Amount was equal to two times the Series Seed Original Issue Price per share, plus unpaid cumulative dividends. In the event that the Proceeds were insufficient to enable the distribution in full of the Liquidation Preference Amount to the holders of the Series Seed for all of the preferred shares held by them, all of the Proceeds were to be distributed among the holders of Series Seed on a pro rata basis. Upon completion of the distribution required to the holders of Series Seed, all of the remaining Proceeds available for distribution to stockholders were to be distributed among the holders of common shares and preferred shares, on an as -converted Voting On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series Seed were entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series Seed held by such holder were convertible as of the record date for determining stockholders entitled to vote on such matter. Holders of Series Seed were entitled to vote together with the holder of common stock as a single class. Holders of Series Seed were entitled to nominate two out of five of the Company’s directors. Equity Incentive Plans The Company’s 2019 Equity Incentive Plan (the “2019 Plan”) was adopted by its board of directors and by its stockholders on July 1, 2019. The Company has reserved 1,400,000 -based In addition, on February 23, 2022 and in connection with the closing of the IPO, the Company’s board of directors adopted the Company’s 2022 Equity Incentive Plan (the “2022 Plan”), which is the successor and continuation of the Company’s 2019 Plan. Under the 2022 Plan, the Company may grant stock options, restricted stock, restricted stock units, stock appreciation rights, and other forms of awards to employees, directors and consultants of the Company. Upon its effectiveness, a total of 1,600,000 -based	Note 6 — Stockholders’ Equity Authorized Capital and Stock Split On November 24, 2021, in connection with the filing of the amended registration statement for an IPO, the Company’s board of directors approved a 4 -for-1 Common Stock As of December 31, 2021 and 2020, there were 3,200,000 The holder of the Company’s common stock is entitled to one vote for each share held of record, and is entitled upon liquidation of the Company to share ratably in the net assets of the Company available for distribution after payment of all obligations of the Company and after provision has been made with respect to each class of stock, if any, having preference over the common stock, currently including the Company’s preferred stock. The shares of common stock are not redeemable and have no preemptive or similar rights. Preferred Stock The Company has authorized 1,150,000 Conversion Each share of the Series Seed is convertible, at the option of the holder, at any time and from time to time, and without the payment of additional consideration by the holder, at a conversion price of $1.52 per share, subject to certain adjustments for stock splits, stock dividends, recapitalizations, and similar corporate transactions, into fully paid and non -assessable -effective Dividends Holders of the Series Seed are entitled to receive cumulative dividends at a per share rate of 8% per annum, compounded annually, on the initial investment amount commencing on the date of issue. Dividends are payable only when, as, and if declared by the Board of Directors or upon a Liquidation Event, as described below. Dividends on Series Seed are in preference to any dividend on the Company’s common stock. As of December 31, 2021, aggregate cumulative dividends total $1,489,803 or $1.30 per Series Seed share. Liquidation Preference In the event of certain voluntary or involuntary acquisition or sale transactions or upon the liquidation, dissolution or winding up of the Company (each, a “Liquidation Event”), the holders of Series Seed shall be entitled to receive out of the proceeds or assets of the Company legally available for distribution to its stockholders (the “Proceeds”), prior and in preference to any distribution of the Proceeds of such Liquidation Event to the holders of common shares by reason of their ownership thereof, an amount (“the Liquidation Preference Amount”) determined based on the provisions of the Company’s COI. The COI provides that the Liquidation Preference Amount be calculated upon the occurrence of a Liquidation Event, based on the Company’s achievement of a Pre -Clinical -Clinical -Clinical -Clinical As of December 31, 2021, and all other historical periods, the Liquidation Preference Amount is equal to two times the Series Seed Original Issue Price per share, plus unpaid cumulative dividends. In the event that the Proceeds shall be insufficient to enable the distribution in full of the Liquidation Preference Amount to the holders of the Series Seed for all of the preferred shares held by them, all of the Proceeds shall be distributed among the holders of Series Seed on a pro rata basis. Upon completion of the distribution required to the holders of Series Seed, all of the remaining Proceeds available for distribution to stockholders shall be distributed among the holders of common shares and preferred shares, on an as -converted Voting On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series Seed will be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series Seed held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Holders of Series Seed will vote together with the holder of common stock as a single class. Holders of Series Seed are entitled to nominate two out of five of the Company’s directors. Stock Transactions On July 1, 2019, the Company entered into a Series Seed Preferred Stock Purchase Agreement (“Purchase Agreement”) with five qualified investors. The investors agreed to purchase and the Company agreed to sell and issue to investors a total of 1,146,138 2019 Equity Incentive Plan The Company’s 2019 Equity Incentive Plan (the “2019 Plan”) was adopted by its board of directors and by its stockholders on July 1, 2019. The Company has reserved 1,400,000 Stock Options During the year ended December 31, 2020, the Company granted options to purchase up to 688,800 The fair value of options granted in 2020 was estimated using the following assumptions: For the 2020 Exercise price $0.01 Term (years) 5.03 – 6.98 Expected stock price volatility 112.2% – 115.2% Risk-free rate of interest 0.37% – 1.76% A summary of stock option information for the year ended December 31, 2021 is presented below: Number of Weighted Total Weighted Outstanding as of December 31, 2020 780,640 $ 0.01 $ 532,787 9.1 Outstanding as of December 31, 2021 780,640 $ 0.01 $ 532,787 8.1 Options vested and exercisable as of December 31, 2021 438,096 $ 0.01 $ 299,001 8.1 Stock-Based Compensation Stock -based For the Years Ended 2021 2020 General and administrative $ 41,061 $ 89,555 Research and development 89,080 245,282 Total $ 130,141 $ 334,837 As of December 31, 2021, future stock -based

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 — Commitments and Contingencies Office lease The Company leased office space for approximately $5,500 a month from a related party. The Company paid a $15,000 rental deposit and rent expense for the three months ended March 31, 2022 and 2021 was approximately $0 and $20,000, respectively. The Company terminated the related party lease in May 2021 and entered into a new lease with an unrelated party in April 2021. The Company is not a party to a lease with a term in excess of 12 months and has a month -to-month Litigation From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. As of March 31, 2022, the Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. See Note 11. Significant agreements Oxford University Innovation Limited Pursuant to the OUI Agreement, as disclosed in Note 5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company is obligated to pay a 6% royalty on all net sales of licensed products, as defined in the OUI Agreement, with an annual minimum royalty payment of $250,000 starting post -product -phase -front -off -licenses Oxford University Research Agreement Pursuant to the terms of the OUI Agreement, as disclosed in Note 5, the Company entered into a sponsored research agreement dated December 18, 2019 with Oxford University for research related to the OUI Agreement for a period of three St. Jude Children’s Hospital Pursuant to the St. Jude Agreement, as disclosed in Note 5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company is obligated to make 4% royalty payments for each licensed product(s) sold by the Company or its affiliates, based on the net sales for the duration of the St. Jude Agreement, and also pay 15% of consideration received for any sublicenses. The Company is required to pay an annual maintenance fee of $10,000 beginning on the first anniversary of the Effective Date (which is waived if all of the developmental milestones scheduled for completion before such annual fee is due have been achieved). In addition, the Company is required to pay St. Jude milestone payments of up to an aggregate of $1 million; specifically, upon the achievement of specified development milestones of approximately $0.2 million, regulatory milestones of approximately $0.3 million, and commercial milestones of approximately $0.5 million. On May 11, 2022, the Company entered into an amendment to the St. Jude Agreement, whereby the royalty terms, milestones payments and licensing fees were amended. See Note 11 for more information on this amendment. As of March 31, 2022, the Company evaluated the likelihood of the Company achieving the specified milestones and generating product sales, and determined the likelihood is not yet probable and as such no accrual of these payments is required as of March 31, 2022. St. Jude Children’s Sponsored Research Agreement In addition to the St. Jude Agreement, the Company also entered into a sponsored research agreement dated May 3, 2021 with St. Jude for research related to the St. Jude Agreement. Pursuant to this research agreement, the Company is obligated to pay St. Jude an aggregate amount of $73,073 in two parts, Phase I for $57,624 and Phase II for $15,449. This sponsored research project began during 2021, and the Company recorded approximately $8,000 in related accrued expenses at December 31, 2021. During the three months ended March 31, 2022, the Company incurred related research and development expenses of approximately $8,000, and had approximately $15,000 recorded as related accrued expenses at March 31, 2022. There were no such expenses incurred during the three months ended March 31, 2021. Cincinnati Children’s Hospital Medical Center Pursuant to the CHMC Agreement, as disclosed in Note 5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company is obligated to pay CHMC a single -digit -royalty Ology Bioservices, Inc. (which was later acquired by National Resilience, Inc.) Pursuant to the Ology MSA and the second Project Addendum, as disclosed in Note 5, the Company is obligated to pay Ology an aggregate amount of approximately $2.8 million, plus reimbursement for materials and outsourced testing which will be billed at cost plus 15%. This project began during 2021, and the Company recorded approximately $164,000 and $115,000 as related accounts payable and accrued expenses, respectively, at December 31, 2021. During the three months ended March 31, 2022, the Company incurred related research and development expenses of approximately $217,000, and had approximately $332,000 recorded as related accrued expenses at March 31, 2022. See Note 4. There were no such expenses incurred during the three months ended March 31, 2021. This project is currently expected to be performed through the fourth quarter of 2023. On April 20, 2022, the Company entered into an amendment to the Ology MSA, whereby the Company’s obligations increased by $0.3 million, specifically related to regulatory support on the project. See Note 11. Underwriter Termination Agreement On February 7, 2022, the Company and its former underwriter, Maxim Group (“Maxim”), entered into a termination agreement, whereby the parties agreed to terminate their engagement of Maxim as the Company’s lead managing underwriter and book runner in connection with the Company’s IPO. Per the terms of the termination agreement, the Company agreed to pay Maxim a termination fee of $300,000, due upon the close of the Company’s IPO. The termination fee was recorded as general and administrative expense during the three months ended March 31, 2022, and is included in accounts payable in the accompanying condensed balance sheet at March 31, 2022. Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may incur charges in the future as a result of these indemnification obligations. Risks and Uncertainties — COVID-19 Management continues to evaluate the impact of the COVID -19	Note 7 — Commitments and Contingencies Office lease The Company leased office space for approximately $5,500 a month from a related party. The Company paid a $15,000 rental deposit and rent expense for the years ended December 31, 2021 and 2020 was approximately $26,000 and $66,000, respectively. The Company terminated the related party lease in May 2021 and entered into a new lease with an unrelated party in April 2021. The Company is not a party to a lease with a term in excess of 12 months and has a month -to-month Litigation From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. Significant agreements Oxford University Innovation Limited Pursuant to the OUI Agreement, as disclosed in Note 5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company is obligated to pay a 6% royalty on all net sales of licensed products, as defined in the OUI Agreement, with an annual minimum royalty payment of $250,000 starting post -product -phase from any sublicensee (including all up -front -off -licenses Oxford University Research Agreement Pursuant to the terms of the OUI Agreement, as disclosed in Note 5, the Company entered into a sponsored research agreement dated December 18, 2019 with Oxford University for research related to the OUI Agreement for a period of three St. Jude Children’s Hospital Pursuant to the St. Jude Agreement, as disclosed in Note 5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company is obligated to make 4% royalty payments for each licensed product(s) sold by the Company or its affiliates, based on the net sales for the duration of the St. Jude Agreement, and also pay 15% of consideration received for any sublicenses. The Company is required to pay an annual maintenance fee of $10,000 beginning on the first anniversary of the Effective Date (which is waived if all of the developmental milestones scheduled for completion before such annual fee is due have been achieved). In addition, the Company is required to pay St. Jude milestone payments of up to an aggregate of $1 million; specifically, upon the achievement of specified development milestones of approximately $0.2 million, regulatory milestones of approximately $0.3 million, and commercial milestones of approximately $0.5 million. As of December 31, 2021, the Company evaluated the likelihood of the Company achieving the specified milestones and generating product sales, and determined the likelihood is not yet probable and as such no accrual of these payments is required as of December 31, 2021. St. Jude Children’s Sponsored Research Agreement In addition to the St. Jude Agreement, the Company also entered into a sponsored research agreement dated May 3, 2021 with St. Jude for research related to the St. Jude Agreement. Pursuant to this research agreement, the Company is obligated to pay St. Jude an aggregate amount of $73,073 in two parts, Phase I for $57,624 and Phase II for $15,449. This sponsored research project began during the year ended December 31, 2021, and the Company has incurred related research and development expenses of approximately $65,000 of which approximately $8,000 was recorded as accrued expenses at December 31, 2021. Cincinnati Children’s Hospital Medical Center Pursuant to the CHMC Agreement, as disclosed in Note 5, the Company is obligated to pay certain milestone and royalty payments in the future, as the related contingent events occur. Specifically, the Company is obligated to pay CHMC a single -digit obligated to pay up to a 25% royalty on any non -royalty Ology Bioservices, Inc. (which was later acquired by National Resilience, Inc.) Pursuant to the Ology MSA and the second Project Addendum, as disclosed in Note 5, the Company is obligated to pay Ology an aggregate amount of approximately $2.8 million, plus reimbursement for materials and outsourced testing which will be billed at cost plus 15%. This project began during the year ended December 31, 2021, and the Company has incurred related research and development expenses of approximately $328,000 of which approximately $164,000 and $115,000 was recorded as accounts payable and accrued expenses, respectively, at December 31, 2021. This project is currently expected to be performed through the fourth quarter of 2023. Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may incur charges in the future as a result of these indemnification obligations. Risks and Uncertainties — COVID-19 Management continues to evaluate the impact of the COVID -19

Related Party Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 8 — Related Party Transactions The Company originally engaged the Chief Executive Officer, who is also the Board Chairman and prior to the close of the IPO, sole common stockholder of the Company, pursuant to a consulting agreement commencing October 22, 2018, which calls for the Company to pay for consulting services performed on a monthly basis. During the three months ended March 31, 2022 and 2021, the Company incurred approximately $63,000 and $105,000 in fees under the consulting agreement, respectively, which are recognized in general and administrative expenses in the accompanying statements of operations. Upon the close of the Company’s IPO, the consulting agreement was terminated and the CEO’s employment agreement became effective. The Company also leased office space from a related party, through common ownership. The lease is further described in Note 7 of these financial statements. The lease was terminated in May 2021, and the related deposit was reclassified to the receivable from related parties balance. As of March 31, 2022 and December 31, 2021, the Company has a receivable from related parties of approximately $165,000 and $153,000, respectively. The balance consists primarily of consulting fee prepayments to the Company’s CEO, in the amount of $140,000 as of March 31, 2022 and December 31, 2021. These consulting fee prepayments were repaid to the Company in lieu of a bonus payout due to the CEO during May 2022. The remaining balance as of March 31, 2022 consists of approximately $18,000 and $7,000 of miscellaneous payments made by the Company on the behalf of the CEO and Chief Business Officer, respectively. The balance due from the Chief Business Officer was repaid to the Company in April 2022. The remaining balance as of December 31, 2021 consists of miscellaneous payments made by the Company on the behalf of the CEO. One of the Company’s directors serves on the Advisory Board for the Cincinnati Children’s Hospital Medical Center Innovation Fund, which is affiliated with CHMC. The Company has an exclusive license agreement with CHMC as disclosed in Note 5. This director resigned from the Company’s board upon the close of its IPO.	Note 8 — Related Party Transactions The Company has engaged the Chief Executive Officer, who is also the Board Chairman and sole common stockholder of the Company, pursuant to a consulting agreement commencing October 22, 2018, which calls for the Company to pay for consulting services performed on a monthly basis. During the years ended December 31, 2021 and 2020, the Company incurred approximately $0.4 million in fees under the consulting agreement, which are recognized in general and administrative expenses in the statements of operations. In addition, during the year ended December 31, 2021, the Company paid the Chief Executive Officer a discretionary bonus of $0.2 million, which is also recognized in general and administrative expenses in the statements of operations. No such bonuses were earned or paid during the year ended December 31, 2020. The Company also leased office space from a related party, through common ownership, and had a rental deposit of $15,000 on the balance sheet as of December 31, 2020. The lease is further described in Note 7 of these financial statements. The lease was terminated in May 2021, and the deposit was reclassified to the receivable from related parties balance. During the fourth quarter of 2021, the amounts due from this related party were determined to be uncollectible and were written off. The total amount written off was approximately $22,000, is recognized in general and administrative expenses in the accompanying statement of operations, and is related to the lease deposit, overpaid rent and utility expenses. As of December 31, 2021 and 2020, the Company has a receivable from related parties of approximately $153,000 and $45,000, respectively. The balance consists primarily of consulting fee prepayments to the Company’s CEO, in the amounts of $140,000 and $35,000 as of December 31, 2021 and 2020, respectively. The remaining balance as of December 31, 2021 consists of miscellaneous payments made by the Company on the behalf of the CEO. The remaining balance as of December 31, 2020 consists of overpaid rent and utility expenses. One of the Company’s directors serves on the Advisory Board for the Cincinnati Children’s Hospital Medical Center Innovation Fund, which is affiliated with CHMC. The Company has an exclusive license agreement with CHMC as disclosed in Note 5.

Income Taxes

Income Taxes	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 9 — Income Taxes No provision for federal, state or foreign income taxes has been recorded for the three months ended March 31, 2022 and 2021. The Company has incurred net operating losses for all of the periods presented and has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements due to uncertainty around utilizing these tax attributes within their respective carryforward periods. The Company has recorded a full valuation allowance against all of its deferred tax assets as it is not more likely than not that such assets will be realized in the near future. The Company’s policy is to recognize interest expense and penalties related to income tax matters as income tax expense. For the three months ended March 31, 2022 and 2021, the Company has not recognized any interest or penalties related to income taxes.	Note 9 — Income Taxes The Company’s major tax jurisdictions are the United States, Florida, and Ohio and the Company does not have any pending tax audits. All of the Company’s tax years are subject to examination by the United States, Florida and Ohio tax authorities. At December 31, 2021, the Company had a net operating loss (“NOL”) carryforward for federal and state income tax purposes totaling approximately $4.9 million and $5.1 million, respectively, available to reduce future taxable income, all of which are carried forward indefinitely for federal tax purposes under the Tax Cuts and Jobs Act. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) signed in to law on March 27, 2020, provided that NOLs generated in a taxable year beginning in 2018 and all subsequent years to date, may now be carried back five years and forward indefinitely. In addition, the limitation of NOL utilization up to 80% of taxable income limitation is temporarily removed, allowing NOLs to fully offset taxable income. Of the state net operating losses, approximately $1.4 million follow the Federal Tax Cuts and Jobs Act and are carried over indefinitely, and approximately $3.7 million will begin to expire in 2024 if not utilized. The NOL carry forward is subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Under the Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company’s net operating loss carryforwards to offset taxable income may be limited based on cumulative changes in ownership. The Company has not completed an analysis to determine whether any such limitations have been triggered as of December 31, 2021. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The tax effects of the temporary differences and carryforwards that give rise to deferred tax assets consist of the following: As of 2021 2020 Deferred tax assets: Net-operating loss carryforward $ 1,120,155 $ 554,813 Stock-based compensation 106,171 91,035 License agreement 59,685 20,848 Accrued compensation 55,500 — Other accrued expenses 14,636 11,247 Gross deferred tax assets 1,356,147 677,943 Valuation allowance (1,353,673 ) (677,943 ) Deferred tax assets, net of allowance $ 2,474 $ — Deferred tax liabilities: Fixed assets (2,474 ) — Total deferred tax liabilities $ (2,474 ) $ — Net deferred tax assets $ — $ — The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company’s history of operating losses since inception, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December 31, 2021 and 2020. During the year ended December 31, 2021, the valuation allowance increased by approximately $0.7 million. The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2021 and 2020, due to the following: For the Years Ended 2021 2020 Expected income tax benefit at Federal statutory tax rate $ (717,640 ) $ (335,888 ) State and local taxes, net of Federal tax benefit (91,233 ) (94,768 ) State rate adjustment 119,413 — Other 13,730 4,884 Change in valuation allowance 675,730 425,772 Provision for income taxes $ — $ — Under U.S. GAAP, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more -likely-than-not

Retirement Plan

Retirement Plan	3 Months Ended
	Mar. 31, 2022
Retirement Benefits [Abstract]
Retirement Plan	Note 10 — Retirement Plan Effective January 1, 2022, the Company adopted a defined contribution savings plan pursuant to Section 401(k) of the Internal Revenue Code (“the 401(k) Plan”). The 401(k) Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees of up to 100% of eligible compensation, subject to the maximum limits imposed by the Internal Revenue Service. The terms of the 401(k) Plan allow for discretionary employer contributions. Enrollment in the 401(k) Plan will become available during the second quarter of 2022. No expenses were incurred related to the 401(k) Plan during the three months ended March 31, 2022.

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 11 — Subsequent Events On April 19, 2022, the Company consummated the closing of a private placement (the “Private Placement”), pursuant to the terms and conditions of a securities purchase agreement, dated as of April 13, 2022. At the closing of the Private Placement, the Company issued 590,406 -funded -Funded -Funded -Funded -Funded are exercised in full. The Preferred Investment Options are exercisable at any time on or after April 19, 2022 at an exercise price of $6.65 per share, subject to certain adjustments as defined in the agreement. The Company agreed to pay Wainwright a placement agent fee and management fee equal to 7.5% and 1.0%, respectively, of the aggregate gross proceeds from the Private Placement and reimburse certain out -of-pocket In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the purchasers, dated as of April 13, 2022 (the “Registration Rights Agreement”). The Registration Rights Agreement provides that the Company shall file a registration statement covering the resale of all of the registrable securities (as defined in the Registration Rights Agreement) with the Securities and Exchange Commission (the “SEC”) no later than the 20 th th th -1 Upon the occurrence of any Event (as defined in the Registration Rights Agreement), which, among others, prohibits the Purchasers from reselling the securities for more than ten consecutive calendar days or more than an aggregate of fifteen calendar days during any 12 -month On April 15, 2022, the Company received a demand letter (the “Demand Letter”) from Boustead. The Demand Letter alleges that the Company breached the Underwriting Agreement entered into between Boustead and the Company, dated February 17, 2022 in connection with the Company’s initial public offering. The Demand Letter alleges that, by engaging Wainwright as placement agent in the Private Placement, the Company breached the right of first refusal to act as placement agent granted to Boustead under the Underwriting Agreement and, as a result of selling securities in the Private Placement, breached the 12 -month -up On April 20, 2022, the Company and Ology entered into a first amendment to the second Project Addendum (the “Ology Amendment”), see Notes 5 and 7. The Ology Amendment provides for an increase to the Company’s obligation of $0.3 million, specifically related to regulatory support on the project. On May 4, 2022, the Company’s compensation committee approved stock option grants under the Company’s 2022 Equity Incentive Plan to the Company’s executive officers, board members, employees and certain consultants. The stock options granted totaled 694,540 options, of which 500,000 were granted to the Company’s executive officers, and all of which have an exercise price of $6.45. On May 11, 2022, the Company and St. Jude entered into a first amendment to the St. Jude Agreement (the “St. Jude Amendment”), see Notes 5 and 7. The St. Jude Amendment provides for a revised development milestone timeline, a one -time	Note 10 — Subsequent Events The Company has completed an evaluation of all subsequent events through March 18, 2022 to ensure that these financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. Except as described below, the Company has concluded that no subsequent event has occurred that requires disclosure. Effective January 1, 2022, the Company adopted a defined contribution savings plan (“the Plan”) pursuant to Section 401(k) of the Internal Revenue Code. The Plan is for the benefit of all qualifying employees and permits voluntary contributions by employees of up to 100% of eligible compensation, subject to the maximum limits imposed by Internal Revenue Service. The terms of the Plan allow for discretionary employer contributions. Enrolment in the Plan will become available on April On February 7, 2022, the Company and its former underwriter, Maxim Group (“Maxim”), entered into a termination agreement, whereby the parties agreed to terminate their engagement of Maxim as the Company’s lead managing underwriter and book runner in connection with the Company’s IPO. Per the terms of the termination agreement, the Company agreed to pay Maxim a termination fee of $300,000, due upon the close of the Company’s IPO. On February 17, 2022, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Boustead Securities, LLC, acting as representative of the underwriters (“Boustead”), in relation to the Company’s IPO, pursuant to which the Company agreed to sell to the underwriters an aggregate of 2,222,222 On February 23, 2022, the Company filed with the Secretary of State of the State of Delaware an amended and restated certificate of incorporation (the “A&R COI”), which became effective immediately. The Company’s board of directors and stockholders approved the A&R COI to be effective upon the closing of the IPO. There was no change to the Company’s authorized shares of common stock and preferred stock of 250,000,000 Upon the close of the Company’s IPO, employment agreements with the Company’s Chief Executive Officer, Chief Financial Officer, and Chief Business Officer became effective. The employment agreements provide for annual compensation of approximately $1.4

Organization, Plan of Business

Organization, Plan of Business Operations	12 Months Ended
	Dec. 31, 2021
Organization, Plan of Business Operations [Abstract]
Organization, Plan of Business Operations	Note 1 — Organization, Plan of Business Operations Blue Water Vaccines Inc. (the “Company”) was formed on October 26, 2018, to focus on the research and development of transformational vaccines to prevent infectious diseases worldwide. The Company’s lead vaccine candidates, BWV -101 -102 -in-class -term -purpose -clinical

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s financial statements relate to the valuation of common stock, stock -based	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s financial statements relate to the valuation of common stock, stock -based
Basis of Presentation	Unaudited Interim Financial Statements The accompanying condensed balance sheet as of March 31, 2022, and the condensed statements of operations, the condensed statements of changes in stockholders’ equity, and the condensed statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements, and in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2022 and its results of operations and cash flows for the three months ended March 31, 2022 and 2021. The financial data and the other financial information disclosed in the notes to these condensed financial statements related to the three -month -Q -K	Basis of Presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of March 31, 2022 and December 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of December 31, 2021 and 2020, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Property and Equipment	Property and Equipment Property and equipment consists of computers and office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight -line three seven -lived	Property and Equipment Property and equipment consists of computers and office furniture and fixtures, all of which are recorded at cost. Depreciation is recorded using the straight -line three seven -lived
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three -tier • • • In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Financial instruments, including cash, prepaid expenses, deferred offering costs, receivables from related parties, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short -term -financial -recurring	Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three -tier • • • In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third -party -process -process	Deferred Offering Costs Deferred offering costs consist of legal, accounting, and other costs incurred through the balance sheet date that are directly related to the Company’s initial public offering and that will be charged to stockholders’ equity upon the completion of the IPO.
Research and Development	Research and Development The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Accrual estimates are based on several factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs. See Notes 5 and 7. In accordance with FASB ASC Topic 730 -10-25-1 Research and Development,	Research and Development The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. When billing terms under research and development contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding obligations as of period end to those third parties. Accrual estimates are based on several factors, including the Company’s knowledge of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have not been materially different from the actual costs. See Notes 5 and 7. In accordance with FASB ASC Topic 730 -10-25-1 Research and Development,
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock -based -employees -date -based -vesting -line The Company estimates the fair value of stock option grants using the Black -Scholes -based Expected Term -based -life Expected Volatility -specific -based Common Stock Fair Value -party Risk -Free Interest Rate -free Expected Dividend The Company recognizes forfeitures of equity awards as they occur.	Stock-Based Compensation The Company expensed stock -based -employees -date -based -vesting -line The Company estimates the fair value of stock option grants using the Black -Scholes -based Expected Term -based -life Expected Volatility Common Stock Fair Value -party Risk -Free Interest Rate -free Expected Dividend The Company recognizes forfeitures of equity awards as they occur.
Fair Value of Common Stock	Fair Value of Common Stock In order to determine the fair value of shares of common stock of the Company when issuing stock options prior to the IPO, its board of directors considered with input from third party valuations, among other things, contemporaneous valuations of the Company’s common stock. Given the absence of a public trading market of the Company’s capital stock prior to its IPO, its board of directors has exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of the Company common and preferred stock, including: • • • • • • • In estimating the fair market value of common stock of the Company, its board of directors first determined the equity value of its business using accepted valuation methods. The Company engaged a third -party After the completion of the IPO, the fair value of each share of common stock is based on the closing price of the Company’s common stock as reported by the Nasdaq Capital Market.	Fair Value of Common Stock In order to determine the fair value of shares of common stock of the Company when issuing stock options and computing their estimated stock -based • • • • • • • In estimating the fair market value of common stock of the Company, its board of directors first determined the equity value of its business using accepted valuation methods. The Company engaged a third -party
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation allowance.	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rate is recognized in operations in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts expected to be realized by the use of a valuation allowance.
Comprehensive Income (Loss)	Comprehensive Income (Loss) The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying condensed financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non -owner	Comprehensive Income (Loss) The Company is required to report all components of comprehensive income (loss), including net income (loss), in the accompanying financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non -owner
Warrants	Warrants The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480 -10 Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity -10 -40 Derivatives and Hedging — Contracts in Entity’s Own Equity -40 -10 -classified If the warrants do not meet liability classification under ASC 480 -10 -40 -40 -40 -classified -classified -classified
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing the net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the Company’s preferred stock, warrants and options. Diluted loss per share excludes the shares issuable upon the conversion of preferred stock, as well as common stock options and warrants, from the calculation of net loss per share if their effect would be anti -dilutive The two -class -class The following securities were excluded from the computation of diluted shares outstanding due to the losses incurred in the periods presented, as they would have had an anti -dilutive Three Months Ended 2022 2021 Options to purchase shares of common stock 780,640 780,640 Series Seed Preferred Stock — 4,584,552 Warrants to purchase shares of common stock 111,111 — Total 891,751 5,365,192	Net Loss Per Share Basic loss per share is computed by dividing the net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the Company’s preferred stock and options. Diluted loss per share excludes the shares issuable upon the conversion of preferred stock, as well as common stock options, from the calculation of net loss per share if their effect would be anti -dilutive The two -class -class The following were excluded from the computation of diluted shares outstanding due to the losses since inception, as they would have had an anti -dilutive Years Ended 2021 2020 Options to purchase shares of common stock 780,640 780,640 Series Seed Preferred Stock 4,584,552 4,584,552 Total 5,365,192 5,365,192
New Accounting Pronouncements	New Accounting Pronouncement s In April 2012, the Jump -Start -public -public In August 2020, the FASB issued ASU No. 2020 -06 Debt — Debt with Conversion and Other Options (Subtopic 470 -20 ) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815 -40 ): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity -06 In October 2020, the FASB issued ASU 2020 -10 -10 In May 2021, the FASB issued ASU 2021 -04 -50 -40 -Classified -classified -classified -04 The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.	New Accounting Pronouncement s In April 2012, the Jump -Start -public -public On February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016 -02 Leases (Topic 842) -term -of-use -02 In December 2019, the FASB issued ASU No. 2019 -12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes -12 -12 -12 In August 2020, the FASB issued ASU No. 2020 -06 Debt — Debt with Conversion and Other Options (Subtopic 470 -20 ) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815 -40 ): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for public business entities except for smaller reporting companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2020 -06 In May 2021, the FASB issued ASU 2021 -04 -50 -40 -Classified -classified -classified The Company’s management does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.
Stock Split		Stock Split On November 24, 2021, the Company’s board of directors approved a 4 -for-1
Immaterial Correction to Previously Issued Financial Statements		Immaterial Correction to Previously Issued Financial Statements During the preparation of the financial statements for the nine months ended September 30, 2021, the Company identified an error in the disclosures related to the Series Seed liquidation preference, see Note 6 for related disclosures and defined terms. In previously issued financial statements, the Liquidation Preference Amount was incorrectly calculated and disclosed in the balance sheet at one times the Original Issue Price per share, plus unpaid cumulative dividends. As discussed in Note 6, the Liquidation Preference Amount has been two times the Original Issue Price per share, plus unpaid cumulative dividends. The Company evaluated this disclosure error based on the guidance provided by the SEC’s Staff Accounting Bulletin Materiality
Fair Value of Financial Instruments		Fair Value of Financial Instruments Financial instruments, including cash, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short -term Fair Value Measurements
Reclassification		Reclassification Certain amounts in the accompanying financial statements have been reclassified to conform to the current period’s presentation. The amounts reclassified were those related to consulting fee prepayments to our Chief Executive Officer (see Note 8), which were previously included in prepaid expenses in the historical balance sheet as of December 31, 2020, and were reclassified to receivable from related parties in the accompanying financial statements. The reclassification did not have any effect on the prior period net loss or cash flows from operations.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of computation of diluted shares outstanding	Three Months Ended 2022 2021 Options to purchase shares of common stock 780,640 780,640 Series Seed Preferred Stock — 4,584,552 Warrants to purchase shares of common stock 111,111 — Total 891,751 5,365,192	Years Ended 2021 2020 Options to purchase shares of common stock 780,640 780,640 Series Seed Preferred Stock 4,584,552 4,584,552 Total 5,365,192 5,365,192

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Schedule of prepaid expenses	As of As of Prepaid research and development $ 69,205 $ 203,910 Prepaid insurance — 4,842 Prepaid other 20,800 25,799 Total $ 90,005 $ 234,551	As of As of Prepaid research and development $ 203,910 $ 233,532 Prepaid insurance 4,842 4,321 Prepaid other 25,799 5,000 Total $ 234,551 $ 242,853
Schedule of accrued expenses	As of As of Accrued license fees $ 227,500 $ 225,000 Accrued research and development 564,634 300,182 Accrued deferred offering costs 187,500 246,236 Accrued compensation 680,537 234,265 Accrued insurance expense 118,988 — Accrued board of directors’ compensation 33,750 — Accrued other 80,529 49,832 Total $ 1,893,438 $ 1,055,515	As of As of Accrued license fees $ 225,000 $ — Accrued research and development 300,182 — Accrued deferred offering costs 246,236 — Accrued compensation 234,265 — Accrued other 49,832 — Total $ 1,055,515 $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of fair value of options	For the 2020 Exercise price $0.01 Term (years) 5.03 – 6.98 Expected stock price volatility 112.2% – 115.2% Risk-free rate of interest 0.37% – 1.76%
Schedule of stock option information	Number of Weighted Total Weighted Outstanding as of December 31, 2020 780,640 $ 0.01 $ 532,787 9.1 Outstanding as of December 31, 2021 780,640 $ 0.01 $ 532,787 8.1 Options vested and exercisable as of December 31, 2021 438,096 $ 0.01 $ 299,001 8.1
Schedule of stock-based compensation expense	For the Years Ended 2021 2020 General and administrative $ 41,061 $ 89,555 Research and development 89,080 245,282 Total $ 130,141 $ 334,837

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets	As of 2021 2020 Deferred tax assets: Net-operating loss carryforward $ 1,120,155 $ 554,813 Stock-based compensation 106,171 91,035 License agreement 59,685 20,848 Accrued compensation 55,500 — Other accrued expenses 14,636 11,247 Gross deferred tax assets 1,356,147 677,943 Valuation allowance (1,353,673 ) (677,943 ) Deferred tax assets, net of allowance $ 2,474 $ — Deferred tax liabilities: Fixed assets (2,474 ) — Total deferred tax liabilities $ (2,474 ) $ — Net deferred tax assets $ — $ —
Schedule of income taxes differs from the statutory federal rate	For the Years Ended 2021 2020 Expected income tax benefit at Federal statutory tax rate $ (717,640 ) $ (335,888 ) State and local taxes, net of Federal tax benefit (91,233 ) (94,768 ) State rate adjustment 119,413 — Other 13,730 4,884 Change in valuation allowance 675,730 425,772 Provision for income taxes $ — $ —

Organization and Basis of Pre_2

Organization and Basis of Presentation (Details)	1 Months Ended
	Feb. 23, 2022$ / sharesshares
Accounting Policies [Abstract]
Initial public offering	2,222,222
Initial public offering price per share (in Dollars per share) | $ / shares	$ 9
Initial public offering, description	Proceeds from the IPO, net of underwriting discounts, commissions, and offering costs of $2.9 million, were $17.1 million.
Convertible common stock shares	5,626,365

Liquidity and Financial Condi_2

Liquidity and Financial Condition (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended
	Apr. 19, 2022	Feb. 23, 2022	Mar. 31, 2022	Dec. 31, 2021
Liquidity and Financial Condition (Details) [Line Items]
Company cash			$ 18.6	$ 1.9
Working capital			16.3	1.4
Accumulated deficit			$ 8	$ 6
Long-term operating description			The Company expects a significant increase in cash outflows as compared to its historical spend for its planned pre-clinical development and clinical trial activities, and as such, it will need to raise additional capital to sustain operations and meet its long-term operating requirements beyond the one year period following the issuance of these financial statements.
Subsequent Event [Member]
Liquidity and Financial Condition (Details) [Line Items]
Net proceeds	$ 7
IPO [Member] | Subsequent Event [Member]
Liquidity and Financial Condition (Details) [Line Items]
Net proceeds		$ 17.2

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies (Details) [Line Items]
Federal depository insurance coverage limit	$ 250,000	$ 250,000
Deferred offering costs	$ 800,000	$ 300,000
Minimum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Property, plant and equipment, useful life	3 years	3 years
Maximum [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Property, plant and equipment, useful life	7 years	7 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted shares outstanding - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Schedule of computation of diluted shares outstanding [Abstract]
Options to purchase shares of common stock	780,640	780,640
Series Seed Preferred Stock		4,584,552	4,584,552	4,584,552
Warrants to purchase shares of common stock	111,111
Total	891,751	5,365,192	5,365,192	5,365,192

Balance Sheet Details (Details)

Balance Sheet Details (Details) - Schedule of prepaid expenses - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of prepaid expenses [Abstract]
Prepaid research and development	$ 69,205	$ 203,910
Prepaid insurance		4,842	$ 4,321
Prepaid other	20,800	25,799	5,000
Total	$ 90,005	$ 234,551	$ 242,853

Balance Sheet Details (Detail_2

Balance Sheet Details (Details) - Schedule of accrued expenses - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of accrued expenses [Abstract]
Accrued license fees	$ 227,500	$ 225,000
Accrued research and development	564,634	300,182
Accrued deferred offering costs	187,500	246,236
Accrued compensation	680,537	234,265
Accrued insurance expense	118,988
Accrued board of directors’ compensation	33,750
Accrued other	80,529	49,832
Total	$ 1,893,438	$ 1,055,515

Significant Agreements (Details

Significant Agreements (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Apr. 20, 2022	May 21, 2021	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Significant Agreements (Details) [Line Items]
OUI Agreement Expiration			10 years	10 years
Intellectual property licenses is recorded as research and development expenses			$ 3,000	$ 11,000	$ 15,000
Research and development expenses				402,104
Ology Bioservices, Inc. [Member]
Significant Agreements (Details) [Line Items]
Aggregate agreement amount initial agreement			4,000,000	4,000,000
Prepaid expenses to remaining prepaid expenses				100,000	100,000
Prepaid expense remaining				48,600	$ 48,600
Aggregate amount		$ 2,800,000	$ 2,800,000	$ 2,800,000
Cost plus, percentage		15.00%	15.00%	15.00%
Accounts payable				$ 164,000
Accrued expenses			$ 332,000	115,000
Incurred related research and development expenses				328,000
Accrued expenses				$ 115,000
Ology Bioservices, Inc. [Member] | Subsequent Event [Member]
Significant Agreements (Details) [Line Items]
Increased in obligation	$ 300,000

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)	Jul. 01, 2019	Feb. 17, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Feb. 23, 2022	Nov. 24, 2021
Stockholders’ Equity (Details) [Line Items]
Common Stock, Shares Authorized							2,300,000
Common stock par value (in Dollars per share)						$ 0.00001
Aggregate shares		2,222,222
Common stock price per share (in Dollars per share)		$ 9
Underwriting discount percentage						8.00%
Other offering costs (in Dollars)						$ 17,100,000
Warrants to purchase shares of common stock						111,111
Exercise price per share (in Dollars per share)						$ 10.35
Warrants exercisable			111,111
Fair value price per share (in Dollars per share)			$ 56.5
Common stock, shares, issued				3,200,000	3,200,000
Conversion price, per shares (in Dollars per share)			$ 1.52	$ 1.52
Offering netting proceeds (in Dollars)			$ 50,000,000	$ 50,000,000
Offering price percentage			300.00%	300.00%
Cumulative dividends, per share			8.00%
Cumulative dividends (in Dollars)			$ 1,586,162	$ 1,489,803
Cumulative dividends per series seed share (in Dollars per share)			$ 1.38
Description of liquidation preference				As of December 31, 2021, and all other prior historical periods, the Liquidation Preference Amount was equal to two times the Series Seed Original Issue Price per share, plus unpaid cumulative dividends.
Shares issued	1,146,138		1,600,000
Preferred stock, shares authorized			10,000,000	10,000,000	1,150,000		1,150,000
Common stock, par value (in Dollars per share)			$ 0.00001	$ 0.00001	$ 0.00001		$ 0.00001
Preferred stock, per share (in Dollars per share)	$ 0.00001		$ 0.00001	$ 0.00001	$ 0.00001		$ 0.00001
Common stock, shares, outstanding				3,200,000	3,200,000
Voting rights				one
Preferred stock, shares issued			0	1,146,138	1,146,138
Preferred stock, shares outstanding			0	1,146,138	1,146,138
Dividends rate of percentage				8.00%
Series seed per share (in Dollars per share)				$ 1.3
Purchase price per share (in Dollars per share)	$ 6.09
Received amount (in Dollars)	$ 6,900,000
Net of offering costs (in Dollars)	$ 45,000
Purchase of shares					688,800
Fair value (in Dollars)					$ 500,000
Stock-based compensation expense (in Dollars)				$ 68,000
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized						250,000,000
Preferred stock par value (in Dollars per share)						$ 0.00001
Common stock, shares, issued			11,048,587	3,200,000
Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Common Stock, Shares Authorized						10,000,000
Common stock par value (in Dollars per share)						$ 0.00001
2019 Equity Incentive Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Shares issued			1,400,000
Series Seed Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares designated			1,150,000			1,150,000
Common stock, shares, issued			0	1,146,138
Shares issued	1,146,138
Preferred stock, shares authorized				1,150,000
Original Issue Price [Member]
Stockholders’ Equity (Details) [Line Items]
Original issue price per share (in Dollars per share)			$ 6.09
Price per share (in Dollars per share)				$ 6.09
2019 Plan [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock issuance				1,400,000
Board of Directors [Member]
Stockholders’ Equity (Details) [Line Items]
Common Stock, Shares Authorized							250,000,000
Preferred stock, shares authorized							10,000,000
Board of Directors [Member] | Series Seed Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized							1,150,000

Commitments and Contingencies (

Commitments and Contingencies (Details)	May 03, 2021USD ($)	May 21, 2021USD ($)	Jan. 31, 2020USD ($)	Dec. 18, 2019EUR (€)	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Apr. 20, 2022USD ($)	Feb. 07, 2022USD ($)
Commitments and Contingencies (Details) [Line Items]
Company leased office space					$ 5,500		$ 5,500
Rental deposit						$ 15,000	15,000
Rent expense					$ 0	$ 20,000	$ 26,000	$ 66,000
Office lease term, description					The Company is not a party to a lease with a term in excess of 12 months and has a month-to-month lease as of March 31, 2022.		The Company is not a party to a lease with a term in excess of 12 months and has a month-to-month lease as of December 31, 2021.
Litigations description					As of March 31, 2022, the Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims.		The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims.
OUI Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Percentage of royalty on net sales					6.00%		6.00%
Minimum Royalty Expense					$ 250,000		$ 250,000
Royalty rate, percentage					3.00%		3.00%
Royalty on sum received from sublicensee, percentage					25.00%		25.00%
Aggregate payments					$ 51,250,000		$ 51,250,000
Specified milestones					2,250,000		2,250,000
Regulatory milestones					9,500,000		9,500,000
Commercial milestones					39,500,000		39,500,000
Accrued payments							0
Oxford Research [Member]
Commitments and Contingencies (Details) [Line Items]
Agreement period				3 years
Total (in Euro) | €				€ 420,000
Prepaid amount			$ 554,802
Prepaid expense					$ 200,000		$ 200,000	$ 400,000
St. Jude Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Percentage of royalty on net sales							5.00%
Royalty on sum received from sublicensee, percentage					15.00%		15.00%
Aggregate payments					$ 1,000,000		$ 1,000,000
Specified milestones					200,000		200,000
Regulatory milestones					300,000		300,000
Commercial milestones					$ 500,000		$ 500,000
Royalty payments percentage					4.00%		4.00%
Annual maintenance fee					$ 10,000		$ 10,000
Aggregate amount	$ 73,073
Accured expenses							8,000
Accrued payments							0
Incurred related research and development expenses							$ 65,000
St Jude Research Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Aggregate amount	73,073
Accured expenses					15,000
Research and development expenses					$ 8,000
CHMC Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Percentage of royalty on net sales					5.00%
Royalty on sum received from sublicensee, percentage					25.00%		25.00%
Aggregate payments					$ 59,750,000		$ 59,750,000
Specified milestones					500,000		500,000
Regulatory milestones					1,250,000		1,250,000
Commercial milestones					$ 58,000,000		$ 58,000,000
Royalty rate decrease, post valid claim expiration					50.00%		50.00%
Option fee					$ 50,000		$ 50,000
Accrued payments							0
Underwriter Termination Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Termination fee									$ 300,000	$ 300,000
Ology Bioservices, Inc. [Member]
Commitments and Contingencies (Details) [Line Items]
Aggregate amount		$ 2,800,000			2,800,000		2,800,000
Accured expenses					332,000		$ 115,000
Research and development expenses					$ (217,000)
Cost plus percentage		15.00%			15.00%		15.00%
Accounts payable							$ 164,000
Incurred related research and development expenses							$ 328,000
Pre-phase III year [Member] | OUI Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Annual maintenance fee					$10,000		$10,000
Phase III year [Member] | OUI Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Annual maintenance fee					$20,000		$20,000
Phase I [Member] | St. Jude Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Aggregate amount	57,624
Phase II [Member] | St. Jude Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Aggregate amount	$ 15,449

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Related Party Transactions (Details) [Line Items]
Fees under consulting agreement	$ 63,000	$ 105,000	$ 400,000	$ 400,000
Receivable from related party	165,000		153,000	45,000
Consulting fee	140,000
Remaining balance	18,000
Miscellaneous payments	$ 7,000
Rental deposit				15,000
Total amount			22,000
Chief Executive Officer [Member]
Related Party Transactions (Details) [Line Items]
Consulting fee			140,000	$ 35,000
General and administrative expenses			$ 200,000

Income Taxes (Details)

Income Taxes (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Income Tax Disclosure [Abstract]
Carryforward for federal and state income tax	$ 4.9
State income tax	$ 5.1
Taxable income percentage	80.00%
State net operating losses	$ 1.4
Operating loss carryforwards	3.7
Valuation allowance	$ 0.7
Uncertain income tax percentage	50.00%

Retirement Plan (Details)

Retirement Plan (Details)	3 Months Ended
	Mar. 31, 2022
Retirement Benefits [Abstract]
Employees compensation percentage	100.00%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)

May 04, 2022

Feb. 07, 2022

Jan. 02, 2022

May 31, 2022

Apr. 20, 2022

Apr. 19, 2022

Feb. 17, 2022

Mar. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Feb. 23, 2022

Nov. 24, 2021

Jul. 01, 2019

Subsequent Events (Details) [Line Items]

License fee (in Dollars)

$ 227,500

$ 225,000

Aggregate shares of common stock

3,200,000

3,200,000

Common stock, price (in Dollars per share)

$ 6.09

Issued to boustead warrants to purchase

111,111

Common stock authorized

250,000,000

250,000,000

2,300,000

Preferred stock authorized

10,000,000

10,000,000

1,150,000

1,150,000

Shares of common stock

1,600,000

Annual compensation (in Dollars)

$ 1,400,000

Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Converted shares of common stock

5,626,365

Warrants exercisable price (in Dollars per share)

$ 10.35

Agent fee, percentage

7.50%

Management fee, percentage

1.00%

Aggregate subscription amount paid percentage

2.00%

Subsequent event, description

the Company’s compensation committee approved stock option grants under the Company’s 2022 Equity Incentive Plan to the Company’s executive officers, board members, employees and certain consultants. The stock options granted totaled 694,540 options, of which 500,000 were granted to the Company’s executive officers, and all of which have an exercise price of $6.45.

License fee (in Dollars)

$ 5,000

Contribution of employees compensation percentage

100.00%

Termination fee (in Dollars)

$ 300,000

Aggregate shares of common stock

2,222,222

Offering expenses (in Dollars)

$ 17,200,000

Issued to boustead warrants to purchase

111,111

Subsequent Event [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Common stock, price (in Dollars per share)

$ 9

Common stock authorized

250,000,000

Subsequent Event [Member] | Preferred Stock [Member]

Subsequent Events (Details) [Line Items]

Preferred stock authorized

10,000,000

Subsequent Event [Member] | Minimum [Member]

Subsequent Events (Details) [Line Items]

Royalty rate

4.00%

Subsequent Event [Member] | Maximum [Member]

Subsequent Events (Details) [Line Items]

Royalty rate

5.00%

Subsequent Event [Member] | Private Placement [Member]

Subsequent Events (Details) [Line Items]

Converted shares of common stock

590,406

Aggregate net proceeds (in Dollars)

$ 7,000,000

Aggregate out-of pocket expenses to placement agent (in Dollars)

$ 85,000

Subsequent Event [Member] | Pre-Funded Warrants [Member]

Subsequent Events (Details) [Line Items]

Aggregates purchase shares

590,406

Purchase price, per share (in Dollars)

$ 6.774

Warrants exercisable price (in Dollars per share)

$ 0.001

Subsequent Event [Member] | Preferred Investment Options [Member]

Subsequent Events (Details) [Line Items]

Aggregates purchase shares

1,180,812

Purchase price, per share (in Dollars)

$ 6.775

Warrants exercisable price (in Dollars per share)

$ 6.65

Subsequent Event [Member] | Wainwright Warrants [Member]

Subsequent Events (Details) [Line Items]

Warrants exercisable price (in Dollars per share)

$ 8.46875

Issued warrants

70,849

Shares percentage

6.00%

Exercise price (in Dollars per share)

$ 8.46875

Ology Amendment [Member] | Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Subsequent event, description

the Company and Ology entered into a first amendment to the second Project Addendum (the “Ology Amendment”), see Notes 5 and 7. The Ology Amendment provides for an increase to the Company’s obligation of $0.3 million, specifically related to regulatory support on the project.

St. Jude Amendment [Member] | Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Subsequent event, description

the Company and St. Jude entered into a first amendment to the St. Jude Agreement (the “St. Jude Amendment”), see Notes 5 and 7. The St. Jude Amendment provides for a revised development milestone timeline, a one-time license fee of $5,000, and an increase to the royalty rate from 4% to 5%. The St. Jude Amendment also provides for an increase to the contingent milestone payments, from $1.0 million to $1.9 million in the aggregate; specifically, development milestones of $0.3 million, regulatory milestones of $0.6 million, and commercial milestones of $1.0 million.

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of computation of diluted shares outstanding - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Schedule of computation of diluted shares outstanding [Abstract]
Options to purchase shares of common stock			780,640	780,640
Series Seed Preferred Stock		4,584,552	4,584,552	4,584,552
Total	891,751	5,365,192	5,365,192	5,365,192

Balance Sheet Details (Detail_3

Balance Sheet Details (Details) - Schedule of prepaid expenses - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of prepaid expenses [Abstract]
Prepaid research and development		$ 203,910	$ 233,532
Prepaid insurance		4,842	4,321
Prepaid other	20,800	25,799	5,000
Total	$ 90,005	$ 234,551	$ 242,853

Balance Sheet Details (Detail_4

Balance Sheet Details (Details) - Schedule of accrued expenses - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of accrued expenses [Abstract]
Accrued license fees	$ 227,500	$ 225,000
Accrued research and development	564,634	300,182
Accrued deferred offering costs		246,236
Accrued compensation	680,537	234,265
Accrued other	80,529	49,832
Total	$ 1,893,438	$ 1,055,515

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of fair value of options	12 Months Ended
	Dec. 31, 2020$ / shares
Stockholders' Equity (Details) - Schedule of fair value of options [Line Items]
Exercise price (in Dollars per share)	$ 0.01
Minimum [Member]
Stockholders' Equity (Details) - Schedule of fair value of options [Line Items]
Term (years)	5 years 10 days
Expected stock price volatility	112.20%
Risk-free rate of interest	0.37%
Maximum [Member]
Stockholders' Equity (Details) - Schedule of fair value of options [Line Items]
Term (years)	6 years 11 months 23 days
Expected stock price volatility	115.20%
Risk-free rate of interest	1.76%

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of stock option information - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of stock option information [Abstract]
Number of Shares, Beginning Balance		780,640
Weighted Average Exercise Price, Beginning Balance		$ 0.01
Total Intrinsic Value, Beginning Balance		$ 532,787
Weighted Average Remaining Contractual Life (in years), Beginning Balance		9 years 1 month 6 days
Number of Shares, Ending Balance	780,640
Weighted Average Exercise Price, Ending Balance	$ 0.01
Total Intrinsic Value, Ending Balance	$ 532,787
Weighted Average Remaining Contractual Life (in years), Ending Balance	8 years 1 month 6 days
Number of Shares, Options vested and exercisable	438,096
Weighted Average Exercise Price, Options vested and exercisable	$ 0.01
Total Intrinsic Value, Options vested and exercisable	$ 299,001
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable	8 years 1 month 6 days

Stockholders' Equity (Details_3

Stockholders' Equity (Details) - Schedule of stock-based compensation expense - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 130,141	$ 334,837
General and administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	41,061	89,555
Research and development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation	$ 89,080	$ 245,282

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of deferred tax assets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net-operating loss carryforward	$ 1,120,155	$ 554,813
Stock-based compensation	106,171	91,035
License agreement	59,685	20,848
Accrued compensation	55,500
Other accrued expenses	14,636	11,247
Gross deferred tax assets	1,356,147	677,943
Valuation allowance	(1,353,673)	(677,943)
Deferred tax assets, net of allowance	2,474
Deferred tax liabilities:
Fixed assets	(2,474)
Total deferred tax liabilities	(2,474)
Net deferred tax assets

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of income taxes differs from the statutory federal rate - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of income taxes differs from the statutory federal rate [Abstract]
Expected income tax benefit at Federal statutory tax rate	$ (717,640)	$ (335,888)
State and local taxes, net of Federal tax benefit	(91,233)	(94,768)
State rate adjustment	119,413
Other	13,730	4,884
Change in valuation allowance	675,730	425,772
Provision for income taxes